Spiral Therapeutics Begins Phase 1 Trial of Hearing Loss Drug

Spiral Therapeutics recently secured $3.7 million as part of a Series A financing round co-led by Savoir Capital and Camden Partners to continue to advance its hearing loss pipeline.